Unfortunately, it is clear in the scientific community that these cannabinoids, including CBD, are very poorly absorbed. CBD shows limited oral bioavailability due to its poor aqueous solubility and extensive first-pass metabolism. To overcome these limitations, a novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology was developed.
A study was conducted with the objective to evaluate the PK profile of the VESIsorb® CBD
formulation in a randomized, double-blind, cross-over design in 16 healthy volunteers under fasted conditions. The study demonstrated that the VESIsorb® delivery system could provide the formulation solution needed to ensure the dramatically improved absorption and bioavailability of CBD that’s necessary to provide the therapeutic health benefits – safely and effectively – that so many are seeking from CBD.
MYCBD products are specifically formulated with VESIorb® to promote the highest possible bioavailability in the CBD market.
Start your wellness journey today!